Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-998-6475
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/20/2020 (Estimated)
OptionableNot Optionable
Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions
What is Seelos Therapeutics' stock symbol?
Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."
When is Seelos Therapeutics' next earnings date?
What price target have analysts set for SEEL?
3 brokers have issued twelve-month price targets for Seelos Therapeutics' shares. Their forecasts range from $4.00 to $8.00. On average, they expect Seelos Therapeutics' stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 422.9% from the stock's current price. View Analyst Price Targets for Seelos Therapeutics.
What is the consensus analysts' recommendation for Seelos Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seelos Therapeutics.
Has Seelos Therapeutics been receiving favorable news coverage?
Headlines about SEEL stock have been trending extremely negative recently, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Seelos Therapeutics earned a news impact score of -5.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Seelos Therapeutics.
Are investors shorting Seelos Therapeutics?
Seelos Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,190,000 shares, an increase of 13.3% from the January 15th total of 1,050,000 shares. Based on an average daily trading volume, of 519,700 shares, the days-to-cover ratio is presently 2.3 days. Currently, 5.9% of the shares of the stock are sold short. View Seelos Therapeutics' Current Options Chain.
Who are some of Seelos Therapeutics' key competitors?
Some companies that are related to Seelos Therapeutics include Axovant Gene Therapies (AXGT), Trillium Therapeutics (TRIL), VERONA PHARMA P/S (VRNA), CV Sciences (CVSI), Sunesis Pharmaceuticals (SNSS), Immunic (IMUX), TFF Pharmaceuticals (TFFP), Vaccinex (VCNX), Trevi Therapeutics (TRVI), Sesen Bio (SESN), AVEO Pharmaceuticals (AVEO), Inflarx (IFRX), Proteostasis Therapeutics (PTI), Oramed Pharmaceuticals (ORMP) and Enlivex Therapeutics (ENLV).
What other stocks do shareholders of Seelos Therapeutics own?
Who are Seelos Therapeutics' key executives?
Seelos Therapeutics' management team includes the folowing people:
- Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59)
Who are Seelos Therapeutics' major shareholders?
Which institutional investors are buying Seelos Therapeutics stock?
How do I buy shares of Seelos Therapeutics?
Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Seelos Therapeutics' stock price today?
One share of SEEL stock can currently be purchased for approximately $1.02.
How big of a company is Seelos Therapeutics?
What is Seelos Therapeutics' official website?
How can I contact Seelos Therapeutics?
Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-998-6475 or via email at [email protected]
MarketBeat Community Rating for Seelos Therapeutics (NASDAQ SEEL)
MarketBeat's community ratings are surveys of what our community members think about Seelos Therapeutics and other stocks. Vote "Outperform" if you believe SEEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SEEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
